29156 Federal Register / Vol. 66, No. 103 / Tuesday, May 29, 2001 / Notices

antagonist, which down-regulate the

function of AM, factor H, and the AM/

fH complex has been achieved.

Collectively, the invention provides

methods for treating conditions such as

cancer or diabetes, via antibodies and

small molecule antagonists.

Adrenomedullin (AM) is expressed in

human cancer cell lines of diverse

origin and functions as a universal

autocrine growth factor, driving

neoplastic proliferation. Experimental

models for use in identifying the role of

AM in pancreatic physiology have been

validated and are available for licensing.

The interesting observations show that

AM inhibits insulin secretion in a dosedependent manner. Further experiments

have shown that a neutralizing antibody

up-regulates insulin release at least fivefold, an effect that is reversed with the

addition of synthetic AM.

Novel Inhibitors of p53 for Treatment of

Neurodegenerative Disorders,

Myocardial Infarction and Other Tissue

Insults

Nigel H. Greig, et al. (NIA)

Serial No. 60/216,388, filed July 6, 2000

Licensing Contact: Norbert Pontzer;

301/496–7736, ext. 284; e-mail:

pontzern@nih.gov

The tumor suppressor protein p53 is

a key modulator of stress responses, and

activation of p53 precedes apoptosis

(programmed cell death) in many cell

types. Conditions that stress tissue, such

as deposition of amyloid b-peptide, may

thus cause tissue degeneration through

activation or up-regulation of p53. This

invention provides novel inhibitors of

p53 and methods of using these

inhibitors for the prevention or

treatment of the stress related tissue

degeneration observed in Alzheimer’s

disease, myocardial infarction and

stroke. In vitro and ex vivo studies

demonstrated that p53 inhibition

protected nerve cells from toxic insults

that otherwise induced programmed cell

death. In a rat model of stroke, p53

inhibition produced a 50% reduction in

stroke volume.

Dated: May 17, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–13346 Filed 5–25–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel

NHLBI, National Research Service Training,

SEP (K’s).

Date: June 28–29, 2001.

Time: 7 PM to 5 PM.

Agenda: To review and evaluate grant

applications.

Place: Chevy Chase Holiday Inn, 5520

Wisconsin Ave., Chevy Chase, MD 20815.

Contact Person: Roy L. White, Phd, Review

Branch, NIH, NHLBI, Rockledge Building II,

6701 Rockledge Drive, Room 7196, Bethesda,

MD 20892, 301–435–0291.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: May 22, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13335 Filed 5–25–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel

ACTION–A–CHF trial Investigating

Outcomes, of Exercise Training.

Date: June 19, 2001.

Time: 2 to 5.

Agenda: To review and evaluate grant

applications.

Place: 5520 Wisconsin Avenue, Chevy

Chase, MD 20815.

Contact Person: Joyce A. Hunter, PhD,

Review Branch, Room 7194, Division of

Extramural Affairs, National Heart, Lung, and

Blood Institute, National Institutes of Health,

Bethesda, MD 20872.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: May 22, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13336 Filed 5–25–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.